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Introduction: The gaps in haemophilia treatment around the world are enormous; 
approximately 60% of an estimated 475 000 individuals are not identified. Of the 187 000 
diagnosed, 30% (57 000) access clotting factor replacement therapy. Since 1996, 
humanitarian aid distributed by the World Federation of Hemophilia (WFH) has played a 
minor, yet vital role providing life- saving clotting factor to countries in emergency 
situations. Donated amounts have been small and sporadic, often salvaging short- dated 
products, providing little opportunity to leverage donations with governments. In 2015, a 
prospective donation programme of 100 million I.U. per year of extended half- life factor 
VIII and IX over 10 years was established, necessitating the development of new logistics 
and training programmes by WFH.
Aim: To measure the impact of a greatly expanded haemophilia humanitarian aid 
program.
Materials and methods: In 2016, the first full year of the expanded programme, WFH, 
distributed products to 58 countries with factor VIII usage <1 I.U. per capita, a level in-
compatible with long- term survival and far below the 4 I.U. FVIII per capita minimum es-
tablished in Europe.
Results: The scope of the programme and utilization data for 2016 indicate primarily use 
for acute bleeding, orthopaedic and emergency surgeries. Compared to 2014, 2016 data 
showed substantial increases in patients served (5.9- fold, from 2119 to 14 579), surgeries 
performed (37- fold) and bleeds treated (6.9- fold). Patients on prophylaxis rose from 0 to 
852, including 458 children under 10 years old.
Discussion: The expanded humanitarian aid programme impacts an estimated 10% of 
individuals with haemophilia previously unable to access treatment.
Conclusion: This programme represents an unprecedented public- private partnership to 
deliver medicines to individuals with no access. Further, the programme offers the pro-
spective opportunity to engage governments to take more responsiblity for increasing 
training, medical management, and product supply in 58 resource constrained countries.
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1  | INTRODUCTION
Severe haemophilia (factors VIII or IX <1%) is a lethal disease left untreated. 
Life expectancies in Western Europe and North America have gradually in-
creased from approximately 20 years in the 1950s1 to approaching normal 
today,2-4 due primarily to widespread availability of clotting factors VIII and 
IX replacement therapies. Early diagnosis and the introduction of primary 
prophylaxis have dramatically improved the lives of individuals with hae-
mophilia. Thus, a near normal life expectancy is feasible in countries where 
reimbursement systems cover the cost for prophylaxis treatment.
This is not the case in resource- constrained countries, which com-
prise 70% of the world’s population, and by extension, up to 70% of 
the world’s individuals with haemophilia, leaving the majority undiag-
nosed with high morbidity and mortality due to uncontrolled bleed-
ing.5-8 In lower income countries, based upon World Bank economic 
ratings, less than 10% of the patients have been identified.9 Of those 
diagnosed globally, only 30% have access to clotting factor, resulting 
in a short life expectancy of 70% of the identified patients and pre-
sumed substantial mortality among those not identified.6-8
The World Federation of Hemophilia (WFH) provides training pro-
grammes for healthcare providers and persons with haemophilia on the 
comprehensive care model for haemophilia and for the development 
of advocacy skills. It has been challenging to obtain government com-
mitments to fund Haemophilia Treatment Centers (HTC) and purchase 
lower cost clotting factors. The provision of small donations of clotting 
factor to individual countries has often not been sufficient impetus to 
convince governments to support haemophilia programmes and even 
basic on- demand therapy for life- threatening bleeds.
The WFH currently represents 134 national member patient orga-
nizations (NMOs) worldwide. An annual global survey is conducted to 
assess the amount of clotting factor utilized as a function of the total 
population (per capita).9 This approach to quantify intracountry usage 
assumes a similar global incidence of haemophilia. Through this pro-
cess, an estimate for I.U. of clotting factor required from basic survival 
to full prophylaxis can be estimated.7
In resource- rich countries, prophylactic use of factor VIII in children and 
adults is the standard of care10,11 and clotting factor concentrates (CFC) up 
to ~10 I.U. per capita are now available.9 In contrast, in resource- constrained 
countries which WFH targets for humanitarian aid, per capita use is often 
well below 1 I.U. per capita, a disparity directly responsible for the observed 
high mortality.7 The recent European Directorate for Quality of Medicine 
(EDQM) recommendation calls for minimum 4 I.U. per capita] to provide 
a prophylaxis strategy to minimize arthropathy.12 We present the first full- 
year results of the expanded WFH Humanitarian Aid Programme (HAP) in 
58 countries consuming <1 I.U. per capita in clotting factor.
2  | HUMANITARIAN AID PROGRAMME 
MATERIALS AND METHODS
2.1 | Goals of the programme
Goals were established and include 1, Reach the majority of quali-
fied countries (<1 I.U. per capita) and treat as many persons with 
haemophilia (PWH) as possible within each country; 2, Increase case 
finding and local government engagement; 3, Give healthcare provid-
ers (HCPs) the opportunity to develop multiple skills in management 
and logistics of PWH; 4, Promote low- dose prophylaxis for children 
under 4 years of age; 5, Decrease as much as possible mortality and 
improve quality of life.
2.2 | Selection criteria
Countries were selected on the basis of the Annual Global Survey of 
clotting factor usage of <1 I.U./capita9 and knowledge of the state of 
the HTC and NMO within a country. Countries selected must have 
the ability to diagnose and distinguish between haemophilia A and B, 
and perform a quantitative or qualitative assay for inhibitor (neutral-
izing antibodies) detection. Product donors are not involved in coun-
try selection, and donations go to countries which import little to no 
product.
2.3 | Logistics
Based on an approved distribution plan, the manufacturer ships prod-
uct as needed to the distribution facilities, where a range of vial sizes 
are stored. A single HTC or the NMO, or the Ministry of Health, is 
designated as the recipient of the donations. From the single point 
of storage within a country, product may be shipped to other HTCs 
within the country under the responsibility of the main centre in each 
country.	For	quantities	≥1	million	I.U.	per	country	per	year,	audits	and	
inspections are carried out by WFH to ensure chain of custody and 
lockable cold storage rooms.
2.4 | Training
WFH training materials were prepared for the expanded programme, 
including factsheets on storage and handling, administration and dos-
age, disposal of material, inhibitor detection, low- dose prophylaxis, 
monitoring for adverse events and product recall instructions. These 
factsheets are supplemented by frequent telephone and email con-
tact and periodic regional and in- country visits. In the visits, training 
is generally conducted over 2 days by WFH staff and volunteers and 
includes didactic information on managing haemophilia as well as case 
reports and case series from recipient physicians on how the product 
has been utilized.
2.5 | Key performance indicators
An online reporting system was developed to identify the actual prod-
uct needs in real time and to provide product utilization metrics in 
each country. A series of Key Performance Indicators (KPI) were iden-
tified to reflect the degree of success in product utilization and the 
purpose for which product was used in patients. Dosing and usage 
of products is the responsibility of the treating physician, and no in-
dividual patient outcome data are collected. Thus, ethics committee 
approvals were not needed.
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3  | RESULTS
Since 1996, the WFH Humanitarian Aid Programme has conducted 
humanitarian aid operations in 90 countries, cumulatively distrib-
uting 322 million I.U. of clotting factor through 2014 (Figure 1). 
Donations were unpredictable, facilitating life- saving interven-
tions but not sustainable on- demand treatment of bleeding epi-
sodes. From 2009, CSL Behring started prospectively providing 
2- 3.3 million I.U. per year of clotting factor, followed by Grifols 
in 2014 donating 20- 30 million I.U. per year, and others, allowing 
some multiyear strategic targeting of donations to support infra-
structure development within a few countries (Table 1). By 2014, 
multiyear agreements were signed with several manufacturers and 
plasma collection agencies for prospective, multiyear donations. 
These donations were used primarily for emergency situations and 
were not sufficient for routine on- demand therapy, non- emergent 
orthopaedic reconstructive surgeries or prophylactic regimens. The 
majority of the major manufacturers do not contribute to a prospec-
tive humanitarian aid programme, despite owning the majority of 
the worldwide market.
In 2014, two companies, Bioverativ (formerly Biogen) and Sobi, 
announced a contribution of 1 billion I.U. of extended half- life (EHL) 
clotting factor to the worldwide bleeding disorders community over 
10 years (Table 1). Of this, the WFH agreed to distribute ~100 million 
I.U. per year over 5 years. The programme began in mid- 2015, and in 
2016, the first full year of the expanded WFH HAP 144 million units of 
all products, including 114 million units of EHL products, were distrib-
uted to 58 countries (Figure 2). The approximate percentage of PWH 
F IGURE  1 Humanitarian aid donations 2002- 2016 [Colour figure can be viewed at wileyonlinelibrary.com]
Supplier Number of units/year (MIUs)
Years of donation 
(inclusive)
Bioverativ- SOBI* 100 2015- 2020
Green Cross 2 2017- 2019
CSL Behring 2- 4 2010- 2018
Grifols 20- 30 2014- 2021
Project Recovery (Biotest and 
Canadian Blood Services)
3 2014- 2017
*Bioverativ was spun off from Biogen in January 2017. MIU, Millions of I.U.s
TABLE  1 Prospective Clotting factor 
donations to WFH
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reached, relative to the total number identified in a country, is listed 
in Figure 2.
To establish the countries most in need of aid, data from the annual 
global survey were utilized.9 This approach to quantify intracountry 
usage assumes a similar global incidence of haemophilia; thus, differ-
ences in prevalence based upon early death and lack of patient iden-
tification do not impact the results. Through this process, an estimate 
for I.U. of clotting factor required for basic survival to full prophylaxis 
can be estimated.7
In 2015- 16, 8 regional humanitarian aid trainings were conducted 
in host countries for 335 physicians from the majority of the 58 do-
nation countries. Educational topics include historical and current 
treatment practices, inhibitor (neutralizing antibody) diagnosis and 
treatment, musculoskeletal complications, dosing of conventional 
and extended half- life products and presentations from individual 
countries on their haemophilia care situations and reports on their 
difficult cases. Specific review of laboratory assays for FVIII and FIX 
as well as methods of inhibitor detection was also conducted.
A series of KPIs were established to quantify the impact of the ex-
panded WFH HAP programme (Table 2). The WFH HAP programme 
has seen marked changes between 2014, when about 21 million 
I.U. were donated, and 2016, the first- year donations exceeded 
100 million I.U. Surgeries rose from 21 in 2014- 675 in 2016. The 
number of countries performing surgery rose from 3 to 22. Patients 
on prophylaxis rose from 0 to 852, including 458 children under 
10 years of age. The total number of patients receiving humanitarian 
aid rose from 2119 to 14 579 (Table 2). Importantly 6 governments, 
Senegal, Egypt, Sri Lanka, Nigeria, Armenia and Kenya, have made 
commitments to increase their support of in- country haemophilia 
programmes.
In 2016, treatment of acute bleeding episodes represented the 
single largest category of utilization, followed by prophylaxis and sur-
gery (Figure 3A and B). Surgeries fell off later in the year, likely due to 
completion of some backlogged reconstructive orthopaedic and cir-
cumcision cases (Figure 3C).
By year end 2016, 42 195 acute bleeding episodes had been treated, 
which included 3% intracranial and 2% intra- abdominal bleeding sites, 
considered life- threatening (Figure 3B). Of the 675 surgeries reported, 
7% were for pseudotumors and 3% were for intracranial haemorrhages 
(Figure 3C), both considered as life- saving or limb- saving procedures.
4  | DISCUSSION
In 2016, an unprecedented supply of clotting factors was donated in 
the first full year of the expanded programme. The WFH HAP col-
lected utilization data show very large increases in product use across 
all treatment populations. Humanitarian aid has transformed from 
variable and unpredictable donations to a sustainable programme in 
which almost half the bleeding episodes that were treated between 
1996 and 2014 were treated in 2016 alone.
The aid reached 58 of the 73 countries with <1 I.U. per capita FVIII 
and the number of patients that benefited increased to 14 579, almost 
7 times the number of patients treated in 2014, or approximately 10% 
of the patients globally who had no access to treatment. The increased 
volume of available products with long shelf life made it possible to 
F IGURE  2 Countries reached and percentage of PWH from those countries receiving humanitarian aid in 2016
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develop treatment plans which go beyond acute treatment of individ-
ual patients in life- threatening situations. This is clear from the number 
of patients who received surgery, which increased almost 37- fold and 
included corrective surgery instead of surgery only for life- threatening 
situations. Furthermore, the WFH has promoted a policy for low- dose 
prophylaxis in children in the WFH HAP programme, because many 
studies have demonstrated that treatment for bleeding does not pre-
vent joint disease and that the costs for prophylactic therapy are similar 
to episodic treatment producing considerably inferior results.13-15 When 
transition to prophylaxis is made, it has led to less use of product for 
acute bleeding, which should be reflected in reporting in future years.
Challenges within HTCs in the recipient countries are high, and 
include lack of laboratory instrumentation and lack of requisite lab re-
agents.16,17 The influx of 10- 100- fold more clotting factor into many 
countries has necessitated the need for new training programmes for 
the haematologists, surgeons and nurses, as well as laboratory person-
nel, for management of patients receiving ongoing infusions.
In these environments, there is a predilection to treat only major 
emergency bleeding episodes and a reluctance to start young children 
on low- dose prophylaxis or immune tolerance therapy due to fear that 
a sufficient supply of product will be unpredictable. However, increased 
confidence in the continuing prospective availability of sufficient clotting 
factor is an incentive to improve care and management, and importantly, 
to perform outreach clinics and diagnose many new cases that now still 
die from bleeding.18-20 HTCs are instructed to keep records and report 
on the usage of every donated vial. Currently, 68% of all donated prod-
uct in 2016 have been reported; some product has not yet been utilized.
A programme of this scope and magnitude has significant limita-
tions. Although product is being distributed to 58 countries under 1 
I.U. per capita FVIII, another 15 countries in this category lack suffi-
cient infrastructure to benefit from the programme. This is due to a 
lack of haemophilia- specific medical expertise and as a consequence 
no identified patients. In addition, home care therapy has not yet be-
come a standard of practice, and many patients are unable to benefit 
as they lack access the treatment centre due to distance or transpor-
tation constraints. Crucial for the continuation of the HA programme is 
closing the circle between donation and treatment. The WFH wants to 
create a reliable and complete system in close collaboration with the 
centres that are benefitting from the programme.
It is important to recognize that the WFH HAP is a means to-
wards the end. This programme cannot begin to match the treatment 
guidelines established in Europe, Australia/New Zealand and North 
America, which include sufficient prophylaxis to prevent nearly all 
bleeding episodes (>7 I.U. per capita). The programme can, however, 
improve and save lives of individual patients, provide the impetus for 
expanded case finding to diagnose and treat more patients and pro-
mote government support of HTCs in the recipient countries. This in 
turn will provide a more receptive environment for treatment inno-
vations that may be available in the future, including gene therapy. 
This paradigm of securing government commitments has successfully 
worked at smaller scale with capacity building programmes in the 
WFH Global Alliance for Progress (GAP).21
Outcome data which reflect the management of patients are not 
currently being collected. In 2018, the WFH will initiate outcome data 
KPI 2014 2016 Fold above 2014
Operational metrics (utilization and process)
Patients treated by HA donations 2119 14 579 5.9
Total donation in MIUs 21 144 5.9
Number of countries receiving 
donations
49 58 1.8
Average age of PWH receiving 
treatment
n/a 20
Total number of infusions n/a 61 232
Impact metrics
Number of countries doing 
surgeries
3 22 6.3
Total number of surgeries 21 795 37
Number of acute bleeds treated 6153* 42 195 6.9
Number of PWH on prophylaxis 0 852 n/a
Number of PWH on prophylaxis 
under 4 years
0 139 n/a
Number of PWH on prophylaxis 
over 4 and under 10 years
0 319 n/a
Activity metrics (Trainings and reporting)
Number of attendees of HA 
workshops
0 335 n/a
HA, Humanitarian Aid; MIU, millions of I.U.s; PWH, persons with haemophilia; n/a, not applicable.
*Estimate.
TABLE  2 Key Performance Indicators 
(KPI) for product utilization before and 
after expansion of the WFH Humanitarian 
Aid Programme
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collection of individual patients through a new project the World Bleeding 
Disorders Registry (WBDR).22 While it will be worldwide and applicable to 
all levels of economic development, it is also intended to capture outcome 
data from many of the HTCs receiving humanitarian aid through collection 
of anonymous individual patient data following informed consent.
One question that arises is whether donations of ~130 million 
I.U. per year are sufficient. As the prevalence of identified cases in 
the countries receiving the donations is generally very low and few 
patients are on prophylaxis or home care therapy, supply appears to 
be adequate at present. However, with increasingly more aggressive 
treatment of bleeding, low- dose prophylaxis, development of home 
treatment and increasing numbers of new patients, demand will 
outstrip supply. If increased quantities were available, expansion of 
low- dose prophylaxis to more patients would be a high priority.
Towards this end, numerous models of corporate partnerships have 
been successfully explored in recent years within the pharmaceutical 
company and disaster relief settings.23-25 While these ventures likely 
are not all purely altruistic, both pharma executives and academicians 
have concluded it is both good business sense and a corporate respon-
sibility to collaborate with non- profits to alleviate human suffering. 
With improved manufacturing technologies, costs of protein produc-
tion are low, and the yearly donations still amount to a very small pro-
portion of total yearly sales of clotting factor (<2%). As only a minority 
of manufacturers donate product, much more recognition of these dual 
mutually beneficial goals is needed. For the biopharma companies sup-
porting the expanded WFH HAP the scope coupled with the financial 
magnitude of the programme is unprecedented in global health care.26
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